Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy

Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy

Cancer immunotherapy requires a specific antitumor CD8+ T cell-driven immune response; however, upon genetic and epigenetic alterations of the antigen processing and presenting components, cancer cells escape the CD8+ T cell recognition. As a result, poorly immunogenic tumors are refractory to conve...

Full description

Bibliographic Details
Main Authors: Salvatore Russo, Sara Feola, Michaela Feodoroff, Jacopo Chiaro, Gabriella Antignani, Manlio Fusciello, Federica D’Alessio, Firas Hamdan, Teijo Pellinen, Riikka Mölsä, Lorella Tripodi, Lucio Pastore, Mikaela Grönholm, Vincenzo Cerullo
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
cancer vaccines
immunotherapy
epigenetic therapy
oncolytic vaccines
oncolytic viruses
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329924000080

Internet

http://www.sciencedirect.com/science/article/pii/S2950329924000080

Similar Items